Foresee Pharmaceuticals
逸達生物科技股份有限公司
Foresee Pharmaceuticals is a Taiwan TPEx-listed biotechnology company; its most advanced asset is CAMCEVI ETM 21 mg (FDA approved, Advanced prostate cancer in adults), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| CAMCEVI ETM 21 mg | — | FDA approved | Advanced prostate cancer in adults | United States | 2025-08-29 | Company disclosure |
| FP-001 / CAMCEVI 42 mg | GnRH agonist | NMPA marketing approval | Advanced prostate cancer in adults | China | 2026-10-12 | Company disclosure |
| FP-020 | — | Phase 2; not yet recruiting | Asthma (Diagnosis); Pulmonary Function; Moderate-to-Severe Asthma | — | 2026-07-20 | Trial registry |
Key events
- CAMCEVI 42 mg China NMPA approval announced (company disclosure)
- Global MMP-12 inhibitor licensing agreement with Primevera announced (company disclosure)